Design and synthesis of potent carboxylic acid DGAT1 inhibitors with high cell permeability

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 2, 2012, Pages 824-828

  Bali, Ustav ^a   Barba, Oscar ^a   Dawson, Graham ^a   Gattrell, William T ^a   Horswill, James G ^a   Pan, David A ^a   Procter, Martin J ^a   Rasamison, Chrystelle M ^a   Sambrook Smith, Colin P ^a   Taylor Warne, Amanda ^a   Wong Kai In, Philippe ^a  

^a Prosidion Ltd   (United Kingdom)

Author keywords

DGAT1; Efflux; Obesity; Permeability

Indexed keywords

CARBOXYLIC ACID; DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; ENZYME INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOGENESIS; STRUCTURE ACTIVITY RELATION;

CACO-2 CELLS; DIACYLGLYCEROL O-ACYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; PERMEABILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84855650314     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.12.050     Document Type: Article

References (13)

1. D.W. Haslam, and W.P.T. James Lancet 367 2006 1540
2. S. Cases, S.J. Smith, Y.W. Zheng, H.M. Myers, S.R. Lear, E. Sande, S. Novak, C. Collins, C.B. Welch, A.J. Lusis, S.K. Erickson, and R.V. Farese Jr. Proc. Natl. Acad. Sci. U.S.A. 95 1998 13018
3. S.J. Smith, S. Cases, D.R. Jensen, H.C. Chen, E. Sande, B. Tow, D.A. Sanan, J. Raber, R.H. Eckel, and R.V. Farese Jr. Nature Genetics 25 2000 87
4. S.J. Stone, H.M. Myers, S.M. Watkins, B.E. Brown, K.R. Feingold, P.M. Elias, and R.V. Farese Jr. J. Biol. Chem. 279 2004 11767
5. G. Zhao, A.J. Souers, M. Voorbach, H.D. Falls, B. Droz, S. Brodjian, Y.Y. Lau, R.R. Iyengar, J. Gao, A.S. Judd, S.H. Wagaw, M.M. Ravn, K.M. Engstrom, J.K. Lynch, M.M. Mulhern, J. Freeman, B.D. Dayton, X. Wang, N. Grihalde, D. Fry, D.W.A. Beno, K.C. Marsh, Z. Su, G.J. Diaz, C.A. Collins, H. Sham, R.M. Reilly, M.E. Brune, and P.R. Kym J. Med. Chem. 51 2008 380
6. A.M. Birch, L.K. Buckett, and A.V. Turnball Curr. Opin. Drug Disc. 13 2010 489
7. R.L. Dow, J.C. Li, M.P. Pence, E.M. Gibbs, J.L. LaPerle, J. Litchfield, D.W. Piotrowski, M.J. Munchhof, T.B. Manion, W.J. Zavadoski, G.S. Wlaker, R.K. McPherson, S. Tapley, E. Sugarman, A. Guzman-Perez, and P. DaSilva-Jardine ACS Med. Chem. Lett. 2 2011 407
8. M.J. Waring Bioorg. Med. Chem. Lett. 19 2009 2844
9. R. Dow, M. Andrews, G.E. Aspnes, G.E. Balan, M. Gibbs, A. Guzman-Perez, K. Kapil, J. LaPerle, J.C. Li, J. Litchfield, M.J. Munchhof, and L.P. Perreault Bioorg. Med. Chem. Lett. 21 2011 6122
10. R. Didziapetris, P. Japertas, A. Avdeef, and A. Petrauskas J. Drug Target. 11 2003 391 406
11. T. Raub Mol. Pharm. 3 2006 3 25
12. For an example of successfully reducing aniline mutagenicity see: M.H. Block, S. Boyer, W. Brailsford, D.R. Brittain, D. Carroll, S. Chapman, D.S. Clarke, C.S. Donald, K.M. Foote, L. Godfrey, A. Ladner, P.R. Marsham, D.J. Masters, C.D. Mee, M.R. O'Donovan, J.E. Pease, A.G. Pickup, J.W. Rayner, A. Roberts, P. Schofield, A. Suleman, and A.V. Turnbull J. Med. Chem. 45 2002 3509
13. Ting, P. C., Lee, J. F., Aslanian, R. G.; WO Patent 2011031628, 2011.